Optimizing a Proteomics Platform for Urine Biomarker Discovery

Abstract

Biomarker discovery approaches in urine have been hindered by concerns for reproducibility and inadequate standardization of proteomics protocols. In this study, we describe an optimized quantitative proteomics strategy for urine biomarker discovery, which is applicable to fresh or long frozen samples. We used urine from healthy controls to standardize iTRAQ (isobaric tags for relative and absolute quantitation) for variation induced by protease inhibitors, starting protein and iTRAQ label quantities, protein extraction methods, and depletion of albumin and immunoglobulin G (IgG). We observed the following: With ongoing advances in mass spectrometry (MS) and proteomics technology, proteomics analysis is progressively occupying a central position in biomarker discovery platforms. Biofluids such as urine and blood are the preferred media for proteomics analysis because of their ease of collection and extensive history of use in clinical laboratory practice. Urine, in particular, is an information-rich fluid that can be collected non-invasively and in large quantities. Many urine proteins are produced or shed in the kidney and urogenital tract (1), making urine a promising proximal source of biomarkers for diseases affecting these structures.However, proteomics-based biomarker discovery in urine faces multiple challenges. Urine proteomics is complicated by low urine protein concentration, variations in pH, and high concentrations of salts and urea or other urine components that interfere with sample processing. The urine proteome can also change with individual variables such as hydration, diurnal change, diet, and physical activity as well as variation in sample collection, processing, and storage. In addition, urine proteomics shares the usual challenges of biomarker discovery in other biofluids such as throughput, cost, and the need for a reproducible and quantitative work flow.Isotopic or isobaric labeling methods to reduce variation, increase throughput, and enable quantitative analysis have been developed to address some of these challenges. One such method, isobaric tags for relative and absolute quantitation (iTRAQ) 1 (2), combines relative and absolute peptide quantification with multiplexing ability to enable an increased throughput as well as simultaneous comparison of up to eight samples within one experimental run. Variations induced by urine sample processing have been systematically evaluated for proteomics analyses using two-dimensional gel electrophoresis (3-6), differential gel electrophoresis (7), and liquid chromatography-coupled mass spectrometry (LC-MS) (5,8,9). However, no systematic analyses of urine sample collection and processing have been reported for iTRAQ.Before utilizing iTRAQ-based quantitative proteomics for urine biomarker discovery, we evaluated the impact of variation in several processing steps (addition of protease inhibitors, the starting protein quantities, quantity of the iTRAQ label, protein extraction methods, and depletion of abundant proteins) on iTRAQ protein identifica...

Sorbitol Dehydrogenase Overexpression and Other Aspects of Dysregulated Protein Expression in Human Precancerous Colorectal Neoplasms: A Quantitative Proteomics Study

“…We chose not to deplete our protein samples of high-abundance proteins (e.g. albumin, IgG), because with the number of tissue samples being analyzed, additional sample preparation steps were considered potential sources of confounding variability (30). As an alternative, each of the 10 pooled iTRAQ-labeled samples (10 experiments) was separated into 12 fractions based on the isoelectric point of peptides, reducing the complexity of our protein matrix and limiting the risk of bias toward the more abundant proteins.…”

The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study

“…However, the unexpected complexity of the human urine proteome, estimated to contain 800 to Ͼ1,000 proteins (10,20), has complicated efforts to identify specific proteins from the mass spectrometric data. In addition, proteomicbased biomarker discovery in urine has been impeded by technical issues, including the wide dynamic range of urine protein concentration, variations in pH, and high levels of salts and urea that interfere with sample processing (1,10). In addition, these studies used mass spectrometric techniques that provide relative, as opposed to quantitative measurements of differentially expressed proteins.…”

Searching for New Biomarkers of Renal Diseases through Proteomics

“…Nagaraj and Mann addressed this problem by assessing urine proteomes of healthy individuals to find reference values for the most abundant proteins using label-free quantification in a manner that overcomes the need for exhaustive fractionation and can be translated to the clinic (29 ). Other efforts to simplify the workflow and address technical aspects are emerging (30,31 ). Urine, despite its shortcomings, seems to be an ideal source of biomarkers because it is collected noninvasively, and only a few organs contribute to its proteome.…”